A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

Ryan Haumschild, PharmD, MS, MBA: Dr Anderson, I’d like to start with you. We’ve talked about guideline recommendations. Can you briefly discuss some of the real-world differences in the treatment ...

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...

Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...

Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.

A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...

SAN FRANCISCO, March 3, 2025 /PRNewswire/ — Eko Health, a leader in artificial intelligence (AI) for the early detection of heart and lung diseases, today announced the publication of a peer-reviewed ...

An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure ...